<DOC>
	<DOCNO>NCT02422589</DOCNO>
	<brief_summary>The purpose study evaluate potential inhibitory effect ceritinib CYP3A4- CYP2C9-mediated metabolism probe drug midazolam warfarin , respectively , administer simultaneously cocktail . The result obtain drug interaction study provide guidance enable update ceritinib label help guide recommendation administration co-medications future clinical trial .</brief_summary>
	<brief_title>A Phase I , Multi-center , Open Label , Drug-drug Interaction Study Assess Effect Ceritinib Pharmacokinetics Warfarin Midazolam Patients With ALK-positive Advanced Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ceritinib</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis stage IIIB ( candidate definitive multimodality therapy ) stage IV NSCLC demonstrate ALKpositive advance tumor , NSCLC , carry ALK genetic alteration ( mutation , translocation amplification ) and/or ALK overexpression progress despite standard therapy , effective standard therapy exist . The test confirm ALKpositivity may perform archival tumor ( obtain since time diagnosis ) , newly obtain tumor sample take prior first day study drug . Results confirm ALKpositive status must available initiate treatment ceritinib . Patients receive prior chemotherapy , ALK inhibitor , biologic therapy , investigational agent , must recover toxicity relate prior anticancer therapy grade ≤ 1 ( CTCAE v 4.03 ) prior start study drug . Patients grade ≤ 2 peripheral neuropathy grade alopecia , nail change skin change allow enter study . Patients treat chemotherapy , biological therapy investigational agent must discontinue treatment least 2 week ( 14 day ) prior start study drug Study Day Patient ability understand provide sign informed consent . Patients know hypersensitivity excipients ceritinib ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) , midazolam warfarin describe local product information . History carcinomatous meningitis . Presence history malignant disease ALKpositive advance tumor diagnose and/or require therapy within past 3 year . Exceptions exclusion include follow : completely resect basal cell squamous cell skin cancer , completely resect carcinoma situ type . Clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month Uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 160 mmHg and/or Diastolic Blood Pressure ( DBP ) ≥ 100 mmHg , without antihypertensive medication . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) . Other Protocol define Inclusion/Exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALK-positive advanced tumor ,</keyword>
	<keyword>midazolam ,</keyword>
	<keyword>warfarin ,</keyword>
	<keyword>ceritinib ,</keyword>
	<keyword>ALK ,</keyword>
	<keyword>CYP3A-4 ,</keyword>
	<keyword>Drug drug intereaction</keyword>
</DOC>